PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Álvaro Rea-Neto

Center for Studies and Research in Intensive Care Medicine, Curitiba, Brazil; Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil; Hospital Santa Casa Curitiba, Curitiba, Brazil.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUL 31, 2026 · JOURNAL ARTICLE

Safety and outcomes of dapagliflozin initiation in critically ill patients with acute kidney injury: A post-hoc analysis of the defender trial.

Journal of Critical Care

A post-hoc analysis from a controlled trial showing no safety signal for dapagliflozin in critically ill AKI patients, with near-neutral effects and physiological stability, but underpowered to detect clinically meaningful benefit or harm.

PromisingCaio A M Tavares Álvaro Rea-Neto Renal Replacement Therapy

Reported

28-day mortality (dapagliflozin v…38% vs 40%

Kidney replacement therapy (dapag…12% vs 18%

Composite death/KRT (dapagliflozi…41% vs 42%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support